AWM
NAVB

Aevitas Wealth Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Aevitas Wealth Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed – – 393
2019
Q1 		$0 Hold
300
– – ﹤0.01% 414
2018
Q4 		$1K Hold
300
– – ﹤0.01% 384
2018
Q3 		$1K Hold
300
– – ﹤0.01% 452
2018
Q2 		$1K Hold
300
– – ﹤0.01% 427
2018
Q1 		$2K Hold
300
– – ﹤0.01% 417
2017
Q4 		$2K Buy
+300
New +$2.54K ﹤0.01% 405

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aevitas Wealth Management's NAVB Position: Q2 2019 in Review

Aevitas Wealth Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 300 shares.

Aevitas Wealth Management first reported a position in NAVB in Q4 2017 and held it in 6 quarters. The position peaked at $2K in Q1 2018. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

  • Aevitas Wealth Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
  • Aevitas Wealth Management sold 300 Navidea Biopharmaceuticals Inc. shares in Q2 2019.
  • Aevitas Wealth Management first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2017 and held it in 6 quarters.
  • Aevitas Wealth Management's Navidea Biopharmaceuticals Inc. position peaked at $2K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Aevitas Wealth Management's 13F filing for Q2 2019, filed 26 Jul 2019.